STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, ...
Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results